linjc16/ctgov huggingface dataset:
Effectiveness Evaluation in Thrombus Aspiration in Patients With STEMI and High Thrombotic Load

Study Overview
=================
Brief Summary
-----------------
This study intends to evaluate thrombus on the basis of different methods for evaluating thrombus load The effect of aspiration on the prognosis of STEMI patients with high thrombotic load Provide a basis for the standardized use of aspiration; at the same time, discover the best benefit groups for thrombus aspiration

Official Title
-----------------
Effectiveness Evaluation in Thrombus Aspiration in Patients With STEMI and High Thrombotic Load

Conditions
-----------------
STEMI

Intervention / Treatment
-----------------
* Procedure: Thrombus aspiration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: (1) Age ≥ 18 years; (2) Voluntary signing of informed consent; (3) Onset of 12 hours STEMI patients who underwent PCI reperfusion therapy within time; (4) The guidewire passes through the lesion and the blood Heavy embolism load (TIMI thrombus classification ≥ 3). Exclusion Criteria: (1) Hemodynamics is unstable or there is cardiogenic shock; (2) After thrombolytic therapy; (3) The expected survival time is less than 6 months due to non-cardiac diseases; (4) Past trips Coronary artery bypass graft patients; (5) Participate in other drug and device research within 30 days; (6) Before surgery, clear active gastrointestinal bleeding or other contraindications for taking dual antiplatelet drugs (7) Patients deemed unsuitable for enrollment by other researchers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Thrombus aspiration<br> | Procedure: Thrombus aspiration<br>* Thrombus aspiration<br>|
| No Intervention: control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse cardiovascular events | Including cardiogenic death, recurring myocardial infarction Stent thrombosis or target vessel revascularization | 3 years |
The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration

Study Overview
=================
Brief Summary
-----------------
This study will investigate the influence of lidocaine temperature on pain during injection of lidocaine. Each participant will receive three injections subcutaneously on the abdomen with different temperatures. After each injection, participants will be asked to evaluate the pain on a Visual analog scale (0-100 mm). It is anticipated that the pain decreases with increasing temperature. The aim of the study is to find a simple method for pain reduction that can be used in clinical practice.

Official Title
-----------------
The Influence of Lidocaine Temperature on Pain During Subcutaneous Administration

Conditions
-----------------
Needlestick Injuries

Intervention / Treatment
-----------------
* Procedure: Low temperature lidocaine injection
* Procedure: Room temperature lidocaine injection
* Procedure: Body temperature lidocaine injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-65 years Exclusion Criteria: Kidney, heart or liver disease Eczema or psoriasis on injection site Neuropathy Regular use of painkillers Hypersensitivity of Lidocaine Pregnancy Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: low temperature<br>Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures | Procedure: Low temperature lidocaine injection<br>* 4 °C<br>|
| Experimental: room temperature<br>Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures | Procedure: Room temperature lidocaine injection<br>* 20 °C<br>|
| Experimental: body temperature<br>Each participant will receive three lidocaine injections subcutaneously on the abdomen at different temperatures | Procedure: Body temperature lidocaine injection<br>* 37 °C<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain | (1) visual analog scale 0-100mm, (2) questionnaire | 60 seconds | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Injections, Temperature, Pain, Healthy volunteers, Lidocaine
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to characterize the acute effects of cannabinoids in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Detailed Description
-----------------
To characterize the acute effects of vaporized THC in women relative to men and to begin probing the mechanisms that may underlie gender differences.

Official Title
-----------------
Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study II

Conditions
-----------------
Cannabis

Intervention / Treatment
-----------------
* Drug: Inhaled THC
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least one lifetime exposure to cannabis Good physical and mental health Exclusion Criteria: Cannabis naïve individuals Major current or recent stressors

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Delta-9-Tetrahydrocannabinol (THC)<br>4 mg vaporized THC will be administered. | Drug: Inhaled THC<br>* 4 mg inhaled THC<br>* Other names: Delta-9-Tetrahydrocannabinol;|
| Placebo Comparator: Placebo<br>Inhaled placebo (no active cannabinoids) | Drug: Placebo<br>* Inhaled placebo (no active cannabinoids)<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from Baseline: Rewarding Effects measured by Visual Analog Scale (VAS) | Subjective measure of THC induced high | Changes in high assessed over the following timepoints: baseline, +60, +80, +120, +180, +300 minutes after start of oral Dronabinol administration. | 
| Change from Baseline: Verbal Learning: Measured by Rey Auditory Verbal Learning Test (RAVLT) | Measured as delay recall on the AVLT | Baseline and +80 minutes after start of oral Dronabinol administration. |
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
Engraftment Syndrome after Autologous Stem Cell Transplant: Retrospective Review in Patients with Multiple Myeloma

Detailed Description
-----------------
A retrospective chart review series will be performed fpr subjects enrolled from 1/1/2006.

Official Title
-----------------
Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Multiple Myeloma, developing engraftment syndrome Exclusion Criteria: Patients with Multiple Myeloma, with no features of engraftment syndrome

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of patients developing Engraftment syndrome following stem cell transplant | A retrospective review where subjects medical records are studied for development of engraftment syndrome 6 months after stem cell transplant | 6 months post-transplant | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Multiple Myeloma, Engraftment syndrome
Submacular Hemorrhage Associated With Retinal Arterial Macro Aneurysm

Study Overview
=================
Brief Summary
-----------------
Evaluation of surgical outcome of vitrectomy with subretinal injection of recombinant tissue-plasminogen activator for submacular hemorrhage associated with retinal arterial macroanuerysms.

Conditions
-----------------
Submacular Hemorrhage, Ruptured Retinal Arterial Macro Aneurysms

Intervention / Treatment
-----------------
* Procedure: Vitrectomy for submacular hemorrhage
* Drug: subretinal injection of tissue-plasminogen activator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The patients with sub macular hemorrhage associated with ruptured retinal arterial macro aneurysms Exclusion Criteria: The eyes with preretinal or intraretinal hemorrhage at the fovea The patients with follow-up less than 3 months

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Vitrectomy<br> | Procedure: Vitrectomy for submacular hemorrhage<br> <br> Drug: subretinal injection of tissue-plasminogen activator<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Displacement of sub macular hemorrhage | Anatomical recovery detected funduscopy and optical coherence tomography | one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Visual acuity | Visual recovery after surgery | one year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Submacular hemorrhage, Vitrectomy, tissue- plasminogen activator
Effectiveness of Motivational Interview in Patients With Dyslipidemia

Study Overview
=================
Brief Summary
-----------------
Evaluate the effectiveness of motivational interviewing to improve lipid control and cardiovascular risk in patients with dyslipidemia.

Official Title
-----------------
Effectiveness of Motivational Interview in Patients With Dyslipidemia Treated in Primary Care Consultations (Dislip-EM Study)

Conditions
-----------------
Patients With Dyslipidemia

Intervention / Treatment
-----------------
* Behavioral: Motivational interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: People diagnosed with dyslipidemia To sign informed consent. Exclusion Criteria: Secondary hypercholesterolemia. Familial hypercholesterolemia. Deficiency syndromes family high density lipoprotein. Subjects with a history of cardiac or cerebrovascular events. Other chronic health problems such as diabetes or severe COPD. Subjects with current diagnosis of cancer. Patients with hepatic or renal disorders . Subjects heavy drinkers. Patients with long standing sick leave (more than 6 months). Pregnant or breastfeeding.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Motivational interview<br> | Behavioral: Motivational interview<br>* Motivational interview<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| lipid levels |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cardiovascular risk |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dyslipidemia, motivational interview, prevention
Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV)

Study Overview
=================
Brief Summary
-----------------
Ocular lesions, including cotton wool spots and retinal hemorrhage, are a common feature of HIV infection and acquired immunodeficiency syndrome (AIDS). The aetiology of these apparently vasoocclusive phenomena in HIV related retinopathy is not well understood. Several hypotheses including infectious damage of the retinal vasculature and altered retinal hemodynamics have been postulated. The latter would be compatible with the theory that the retina of HIV patients is hypoxic. However, direct measurement of oxygen tension in the retina is not possible and indirect methods have to be employed. The study objective was to investigate the reactivity in retinal blood flow to 100% oxygen breathing in patients with HIV.

Official Title
-----------------
Retinal Oxygen Reactivity in Patients Infected With Human Immunodeficiency Virus (HIV).

Conditions
-----------------
HIV Infections, Retina, Ocular Physiology

Intervention / Treatment
-----------------
* Drug: 100% O2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Group 1 (Patients with HIV) Aged between 19 and 70 years, male and female HIV positive patients without HIV-related retinopathy with a CD4+ cell count  500 cells/mm3 stage A2, A3, B2, B3, C2 and C3. Best corrected visual acuity >= 0.8 Ametropy < 6 dpt Group 2 (Healthy control subjects) Aged between 19 and 70 years Age and sex matched to the subjects in the HIV group (group matched) Matched with regard to the smoking habits in the HIV group Best corrected visual acuity >= 0.8 Ametropy < 6 dpt Exclusion Criteria: Evidence of any other eye disease Diabetes mellitus Systemic hypertension (defined as SBP > 150 mmHg or DBP > 90 mmHg) Abuse of illegal drugs

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 100% O2|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reactivity in retinal blood flow during 100% O2 breathing expressed as percent change |  |  |
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential

Study Overview
=================
Brief Summary
-----------------
According to the National Burn Repository 2007, the most common type of burn injury is a partial thickness burns. The current standard of care for partial thickness burns is two weeks of topical therapy and wound care. Burns that do not heal within two weeks undergo surgical excision and skin grafting.

Detailed Description
-----------------
Researcher can use the combination of Modulated Imaging and Laser Speckle Imaging can be used as an adjuvant to standard clinical evaluation to gauge burn wound and severity of infection. Researcher can image the burn wounds of and compare with current standard of care, clinical exam, and can use the outcomes information in terms of time to healing and treatment Modulating Imaging is a noninvasive optical modality measure the metabolic functions of the burn wound. Laser Speckle Imaging is a noninvasive optical modality can measure blood flow of burn wound.

Official Title
-----------------
Ability of Modulated Imaging and Laser Speckle Imaging to Determine Burn Wound Severity and Healing Potential

Conditions
-----------------
Skin Burn Multiple

Intervention / Treatment
-----------------
* Device: Modulated Imaging and Laser Speckle Imaging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male / female all age Subjects is an inpatient or out patient with burn wound Exclusion Criteria: Subjects cannot lied flat and still for the duration of the imaging Subjects pregnant.

Ages Eligible for Study
-----------------
Minimum Age: 1 Minute

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Burn wound<br>Modulated Imaging and Laser Speckle Imaging | Device: Modulated Imaging and Laser Speckle Imaging<br>* wound healing<br>* Other names: MI-LSI developed at UCI Beckman Laser Institute;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Noninvasive burn wound severity assessment | Noninvasive burn wound severity assessment using noncontact optical device | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
burn wound
Diagnostic of Rotator Cuff Calcific Tendinosis Using MRI With ZTE Sequence

Study Overview
=================
Brief Summary
-----------------
Conventional radiographs are still considered the reference for identifying rotator cuff calcific tendinosis. MRI is widely performed for rotator cuff disorders evaluation but has a moderate accuracy in rotator cuff calcific tendinosis diagnosis and calcific deposits identification (sensitivity and specificity around 60%), even though it helps in determining acuity of the finding by adjacent soft tissue edema depiction and differential diagnosis identification (i.e. adhesive capsulitis, sub-acromial bursitis…). Zero echo time (ZTE) MRI provides enhanced bone contrast by enabling the acquisition of signals from tissues exhibiting the shortest T2 values on a single sequence with a spatial resolution of 0.8-1.2 mm isotropic and can therefore provide images similar to those obtained with radiographs. We hypothesize that ZTE images could also depict rotator cuff calcific tendinosis, but to our knowledge, no study compared this technique to radiographs and/or standard MRI.

Official Title
-----------------
Diagnostic of Rotator Cuff Calcific Tendinosis Using MRI With ZTE Sequence

Conditions
-----------------
Cuff Rotator Tendinitis

Intervention / Treatment
-----------------
* Diagnostic Test: MRI


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patient referred to the imaging department for a MRI scan in case of suspicion of rotator cuff tendinosis Exclusion Criteria: incomplete data sets

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cases<br>cases of rotator cuff calcific tendinosis on imaging studies | Diagnostic Test: MRI<br>* retrospective review of shoulder MRI<br>|
| witnesses<br>differential diagnosis or normal cases | Diagnostic Test: MRI<br>* retrospective review of shoulder MRI<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| calcific deposits presence | presence of signal hyperintensity within the tendon on MRI ZTE sequence | Retrospective review of all MRI scans, performed at a maximum of 1 year before the reading, during two reading sessions, with an interval of 15 days, in october and november 2022 |